(Q53327026)

13 May 2018

title

Plasmin system of Alzheimer's disease patients: CSF analysis. (English)

1 reference

13 May 2018

1 reference

1

1 reference

13 May 2018

Vincenzo Dinallo

object named as

Vincenzo Dinallo

7

0 references

author name string

Giulia M Sancesario

2

1 reference

13 May 2018

Zaira Esposito

3

1 reference

13 May 2018

Marzia Nuccetelli

4

1 reference

13 May 2018

Roberto Sorge

5

1 reference

13 May 2018

Amanda Formosa

6

1 reference

13 May 2018

Giorgio Bernardi

8

1 reference

13 May 2018

Sergio Bernardini

9

1 reference

13 May 2018

Giuseppe Sancesario

10

1 reference

13 May 2018

publication date

14 March 2012

1 reference

13 May 2018

Journal of Neural Transmission

published in

1 reference

13 May 2018

volume

119

1 reference

13 May 2018

issue

7

1 reference

13 May 2018

page(s)

763-769

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.1007/s00702-012-0778-y

exact match

0 references

cites work

Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Plasminogen and plasmin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Abeta-degrading enzymes in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Plasminogen activator-plasmin system and neuronal migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Clearing the brain's amyloid cobwebs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0778-Y

Laminin degradation by plasmin regulates long-term potentiation

21 January 2018

1 reference

12 December 2020

The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration.

1 reference

12 December 2020

Plasminogen activator release at the neuronal growth cone

1 reference

12 December 2020

Plasminogen activator inhibitors

1 reference

12 December 2020

Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates

1 reference

12 December 2020

Activators and inhibitors of the plasminogen system in Alzheimer's disease.

1 reference

12 December 2020

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

1 reference

12 December 2020

Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease.

1 reference

12 December 2020

Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice

1 reference

12 December 2020

Directed plasminogen activation at the surface of normal and malignant cells

1 reference

12 December 2020

The plasmin system is induced by and degrades amyloid-beta aggregates

1 reference

12 December 2020

10.1007/S00702-012-0778-Y

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

22415062

1 reference

13 May 2018